The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Author: Michele B. Kaufman, PharmD, BCGP

Michele B. Kaufman, PharmD, BCGP

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer and editor. She is also a pharmacist at New York Presbyterian Hospital–Lower Manhattan campus. She has been a past guest lecturer at Touro College of Pharmacy in New York City for the Medical Writing elective. Dr Kaufman is a member of the New York City Society of Health-Systems Pharmacy, the New York State Council of Health-System Pharmacists, the Academy of Managed Care Pharmacy (AMCP)—Northeast Region Affiliate Chapter, the American Society of Consultant Pharmacists and the Empire State-Metropolitan NY Chapter of the American Medical Writers Association. She received her BS in Pharmacy from the University of Rhode Island (URI) College of Pharmacy and her Doctor of Pharmacy degree from Massachusetts College of Pharmacy and Allied Health Sciences in Boston. She also completed a Drug Information Fellowship at the URI Drug Information Center/Roger Williams Medical Center in Providence, R.I. Dr Kaufman is a registered pharmacist and is a Board-Certified Geriatric Pharmacist.

Articles by Michele B. Kaufman, PharmD, BCGP

Research Outlines Benefits of bDMARDs to Treat Early RA

February 10, 2021 • By Michele B. Kaufman, PharmD, BCGP

Sapart et al. suggest a combination of methotrexate and biologic disease-modifying anti-rheumatic drugs as induction therapy for patients with early RA may lead to long-term remission.... [Read More]

Study Examines Tofacitinib’s Long-Term Cardiovascular Risk & More

February 8, 2021 • By Michele B. Kaufman, PharmD, BCGP

In a post-marketing safety study, tofacitinib did not prove non-inferior to tumor necrosis factor inhibitors when evaluated for its long-term effects on heart disease, malignancies and serious infections in RA patients.... [Read More]

European Commission Approves Upadacitinib for Psoriatic Arthritis & Ankylosing Spondylitis

February 4, 2021 • By Michele B. Kaufman, PharmD, BCGP

In January, upadacitinib was approved for use in Europe as a 15 mg, once-daily dose to treat patients with psoriatic arthritis and ankylosing spondylitis.... [Read More]

FDA Approves New Rituximab Biosimilar & Anakinra to Treat a Rare Disease

February 2, 2021 • By Michele B. Kaufman, PharmD, BCGP

The FDA has approved anakinra to treat a rare autoinflammatory disease, deficiency of interleukin 1 receptor antagonist. The administration also approved a new rituximab biosimilar, Riabni, for multiple indications.... [Read More]

Risankizumab May Improve Symptoms of PsA

January 21, 2021 • By Michele B. Kaufman, PharmD, BCGP

Results from two recent phase 3 clinical trials show risankizumab significantly improved the skin and joint symptoms of patients with psoriatic arthritis compared with placebo. ... [Read More]

Hydroxychloroquine Cardiotoxicity in RA Patients

January 5, 2021 • By Michele B. Kaufman, PharmD, BCGP

Hydroxychloroquine may not increase the risk of cardiotoxicity in RA patients, according to findings presented during ACR Convergence 2020.... [Read More]

Long-Term Safety of Baricitinib for RA

December 14, 2020 • By Michele B. Kaufman, PharmD, BCGP

Baricitinib appears to be a safe long-term treatment for RA patients, according to a recent analysis of patients with drug exposure up to eight years.... [Read More]

Patients Demonstrated Good Medication Adherence While Taking Biosimilar Treatment

December 7, 2020 • By Michele B. Kaufman, PharmD, BCGP

Researchers found half of patients taking the biosimilar infliximab-dyyb (Inflectra) remained highly adherent to medication use after 12 months.... [Read More]

Effects of Warfarin on Risk of Hip & Knee Replacement in OA Patients

December 4, 2020 • By Michele B. Kaufman, PharmD, BCGP

The use of warfarin may increase the risk of knee or hip replacement in patients with osteoarthritis (OA), according to research presented during ACR Convergence 2020.... [Read More]

Emergency Use Approved for Baricitinib with Remdesivir Combination Therapy for SARS-CoV-2

December 3, 2020 • By Michele B. Kaufman, PharmD, BCGP

The FDA issued an emergency use authorization for the use of baricitinib combined with remdesivir to treat patients hospitalized with COVID-19.... [Read More]

  • 1
  • 2
  • 3
  • …
  • 35
  • Next Page »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

This site uses cookies: Find out more.